Lu Guoyi, Vice chairman of Zhigong Party Central Committee, and Wang Xuefeng, Chairman of Jiangsu Province Committee, visited Bigway Eye Health Science Center to guide the work

July 13, 2023.Lu Guoyi, member of the Standing Committee of the CPPCC National Committee, Deputy Director of the Committee for Hong Kong, Macao and Taiwan Overseas Chinese, Vice Chairman and Secretary-General of the Zhigong Party Central Committee;Wang Xuefeng, Director of the Central Committee for Overseas Students of Zhigong Party, Chairman of Jiangsu Provincial Committee, Director of Jiangsu Provincial Department of Housing and Urban-Rural Development;Wang Dehua, director of the Incubator management Office of the Torch Center of the Ministry of Science and Technology, and other leaders came to Suzhou Pioneer Park to investigate and guide the work.The first stop of the trip came to the Big Vision Eye Health Science Museum, accompanied by Chen Xinjian, chairman of Big Vision Medical.

Lu Guoyi and other leaders visited Big Vision Eye Health Science Museum to guide the work

Research purpose

In this survey, new problems will be found, new paths will be explored, new insights will be put forward, scientific and professional conclusions will be obtained, research reports and relevant proposals will be submitted to the CPC Central Committee, and suggestions will be provided for China’s international scientific and technological exchange and cooperation, as well as the construction of world important talent centers and innovation highland. It serves the decision-making and development of the Party and the government.

Company profile

Big Vision Medical Technology is a high-tech enterprise founded by state-level talents. The founder Chen Xinjian is a member of China Zhigong Party. In June 2022, Big Vision Medical Eye Health Center opened. Under the care and guidance of Jiangsu Provincial Party Committee and Suzhou Municipal Party Committee, Big Vision Medical Eye Health Center was listed as “Zhifu Zhifu bright care eye health base”.

Research summary

Chen Xinjian, chairman of Big Vision Medical Technology, reported the product technology, core team and development history of Big Vision Medical Technology to the leaders and his party, including member of the Standing Committee of the CPPCC National Committee, Deputy director of the Committee for Hong Kong, Macao and Taiwan Compatriots and Overseas Chinese, Vice Chairman and Secretary General of the Central Committee of the Zhigong Party, Lu Guoyi. MIAS, a dual-modality artificial intelligence-based diagnosis system for ophthalmic imaging pioneered by Big Vision Medical, was introduced. Different from the mainstream products based on fundus color photography in the industry, the advantage of MIAS is that it integrates three-dimensional images of optical coherence tomography (OCT) and two-dimensional images of fundus color photography, which can analyze more fundus diseases more accurately. At present, it can realize the auxiliary diagnosis of more than 20 common ophthalmic diseases such as diabetic retinopathy, macular degeneration, glaucoma and so on. It represents the international advanced level in the field of artificial intelligence analysis and diagnosis of ophthalmic medical imaging, and can be better applied to primary screening and auxiliary diagnosis in hospitals.

Ophthalmic Image Storage Processing and Analysis System (MIAS)
Optical coherence Tomography (AI·OCT)

Professor Chen Xinjian introduced the company in detail, and Lu Guoyi and other leaders gave a high evaluation of Big Vision Medical products and technology. He encouraged Big Vision Medical to maintain cutting-edge research and development capabilities, accelerate enterprise development, and actively promote the application of artificial intelligence in ophthalmic diagnosis and treatment, so as to make greater contributions to the development of medical artificial intelligence in China.

In the future, Big Vision Medical will continue to promote the application of ophthalmic AI in clinical diagnosis, treatment and screening, boost the ability of primary ophthalmic diagnosis and treatment through AI, so that more primary patients can enjoy high-quality ophthalmic AI services, and contribute scientific and technological strength to the early detection, early diagnosis and early treatment of eye diseases.

No comments yet.

Leave a comment

Your email address will not be published.